Ocular Therapeutix, Inc. (NASDAQ:OCUL) registered a -6.26% decrease, still its new closing price is 59.41% up from the company’s 1 year high of 14.50.It posted -14.70% losses in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 5 stock analysts following this company have an average price target at $28.40, with individual PT in the $13.00-$60.00 range. The shares moved at $6.44, implying that brokerage firms see shares gaining about 5.23% in twelve months time.
Ocular Therapeutix, Inc. (OCUL) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a -23.06% fall year to date. A President and CEO, 10% Owner at Ocular Therapeutix, Inc. (OCUL) acquired shares in a transaction closed on Thursday December 15, 2016. Sawhney Amarpreet bought 45,300 shares in the company at $7.85 each and collected $355,001 in proceeds. Sawhney Amarpreet now owns 2,636,332 shares in the company after this transaction. A President and CEO, 10% Owner in the company, Sawhney Amarpreet, disclosed a transaction on Thursday June 09, 2016 that ended up paying $67,000 from the purchase of 10,000 shares at $6.7 per share.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Upcoming Results on Tap
Ocular Therapeutix, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.51 in that period. Sales during the quarter are predicted to arrive at $1.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.39. The mean forecast was for $0 and $-0.50 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.46/share.
Ocular Therapeutix, Inc. (OCUL) Brokerage Update
Ocular Therapeutix, Inc. (OCUL) is in Morgan Stanley’s research list so their analyst rating change is noteworthy. These shares were upgraded to Overweight from Equal-Weight by Morgan Stanley, according to news reported on Wednesday February 17, 2016.Another important research note was issued by Morgan Stanley on Friday October 23, 2015.The firm downgraded OCUL to Equal-Weight from Overweight. Over the last six months and over the last three months, the shares of Ocular Therapeutix, Inc. (OCUL), have changed 47.37% and 5.23%, respectively.
